|
Cancer
and HIV drugs to be under strict price monitoring
While the Sandhu Committee has, in its Interim Report, made
recommendations on controlling the retailer trade margins,
the Committee is finding it tough to evolve an objective criteria
to bring under price control such essential drugs as the anti-HIV
or anti-cancer medicines.
Rofecoxib
withdrawal fine, ground reality different
It is more than a month since the DCGI announced the withdrawal
of the arthritis drug rofecoxib on October 12, 2004, but as
yet there are is no official notification, nor communications
to this effect from companies, nor any processes initiated
by any of the players in the market.
|
